(Q48265627)

10 February 2018

title

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. (English)

1 reference

10 February 2018

relapsing-remitting multiple sclerosis

main subject

0 references

0 references

1 reference

2

Gavin Giovannoni

1 reference

10 February 2018

3

Krzysztof Selmaj

1 reference

10 February 2018

Ralf Gold

1

object named as

Ralf Gold

1 reference

10 February 2018

author name string

Eva Havrdova

4

1 reference

10 February 2018

Xavier Montalban

5

1 reference

10 February 2018

Ernst-Wilhelm Radue

6

1 reference

10 February 2018

Dusan Stefoski

7

1 reference

10 February 2018

Randy Robinson

8

1 reference

10 February 2018

Katherine Riester

9

1 reference

10 February 2018

Jitesh Rana

10

1 reference

10 February 2018

Jacob Elkins

11

1 reference

10 February 2018

Gilmore O'Neill

12

1 reference

10 February 2018

SELECT study investigators

13

1 reference

10 February 2018

language of work or name

English

0 references

publication date

4 April 2013

1 reference

10 February 2018

published in

The Lancet

1 reference

10 February 2018

volume

381

1 reference

10 February 2018

page(s)

2167-2175

1 reference

10 February 2018

issue

9884

1 reference

10 February 2018

Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

Immunohistochemical identification of T-lymphocytes in the central nervous system of patients with multiple sclerosis and subacute sclerosing panencephalitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

Normalized accurate measurement of longitudinal brain change.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

Current and emerging therapies in multiple sclerosis: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

Disability as an outcome in MS clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

Surrogate endpoints for EDSS worsening in multiple sclerosis: A meta-analytic approach

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

The incomplete nature of multiple sclerosis relapse resolution

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

The biology of interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

Immune responses in interleukin-2-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

CD25 appears non essential for human peripheral T(reg) maintenance in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2962190-4

7 January 2021

10.1016/S0140-6736(12)62190-4

Identifiers

DOI

1 reference

10 February 2018

PubMed ID

23562009

1 reference

10 February 2018